First-generation anti-tumour antibodies clinical disappointment

First-generation anti-tumour antibodies clinical disappointment 

Despite the scientific elegance of the antibody-mediated approach to tumour detection/ destruction, initial clinical trials proved disappointing. A number of factors contributed to their poor therapeutic performance, particularly against solid tumours. Most such factors relate directly or indirectly to the fact that the first generation of such drugs utilized whole monoclonal antibody preparations of murine origin. These factors include  

---